Insurance Approval for Sofosbuvir and Simeprevir-Based Hepatitis C Therapies

被引：0
|
作者：
George, Khalid [1 ]
Weick, Alexander [1 ]
Moonka, Dilip [2 ]
Segovia, Maria [2 ]
Jafri, Syed-Mohammed [2 ]
机构：
[1] Henry Ford Hosp, Dept Internal Med, Detroit, MI 48202 USA
[2] Henry Ford Hosp, Dept Gastroenterol & Hepatol, Detroit, MI 48202 USA
来源：
AMERICAN JOURNAL OF GASTROENTEROLOGY | 2014年 / 109卷
关键词：
D O I：
10.14309/00000434-201410002-00613
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
613
引用
收藏
页码：S178 / S179
页数：2
相关论文
共 50 条
  • [1] Serious Adverse Events and Hepatic Decompensation in Hepatitis C Virus infected Patients on Sofosbuvir- and/or Simeprevir-based Therapies
    Perumalswami, Ponni
    Bichoupan, Kian
    Yalamanchili, Rachana
    Harty, Alyson
    Gardenier, Donald
    Ng, Michel
    Motamed, David B.
    Khaitova, Viktoriya
    Bach, Nancy
    Chang, Charissa Y.
    Im, Gene Y.
    Leong, Jennifer
    Ku, Lawrence
    Schiano, Thomas D.
    Dieterich, Douglas
    Branch, Andrea D.
    [J]. HEPATOLOGY, 2014, 60 : 694A - 695A
  • [2] THE COST-EFFECTIVENESS OF SOFOSBUVIR- AND SIMEPREVIR-BASED THERAPIES FOR HCV GENOTYPE 1 INFECTION
    Linas, B. P.
    Morgan, J. R.
    Pho, M. T.
    Leff, J. A.
    Schackman, B. R.
    Assoumou, S. A.
    Salomon, J. A.
    Freedberg, K. A.
    Kim, A. Y.
    [J]. JOURNAL OF HEPATOLOGY, 2015, 62 : S633 - S633
  • [3] Efficacy and safety of telaprevir- and simeprevir-based triple therapies for older patients with chronic hepatitis C
    Satoshi Yamagiwa
    Toru Ishikawa
    Nobuo Waguri
    Soichi Sugitani
    Hiroto Wakabayashi
    Shogo Ohkoshi
    Takashi Tsukishiro
    Toru Takahashi
    Toshiaki Watanabe
    Shuji Terai
    [J]. World Journal of Hepatology, 2017, (05) : 252 - 262
  • [4] Initiating Sofosbuvir Based Therapies for Hepatitis C - Does Insurance Matter?
    Shah, Neeral L.
    Kelly, Virginia L.
    Pourkazemi, Yassaman
    Hojnowski, Kristen L.
    Klein, Lauren J.
    Henry, Zachary
    Caldwell, Stephen H.
    [J]. GASTROENTEROLOGY, 2015, 148 (04) : S1102 - S1103
  • [5] The Economic Impact of Sofosbuvir- and Simeprevir-based HCV Treatment in the United States
    Chhatwal, Jagpreet
    Kanwal, Fasiha
    Roberts, Mark S.
    Dunn, Michael A.
    [J]. HEPATOLOGY, 2014, 60 : 255A - 256A
  • [6] Telaprevir-based and simeprevir-based interferon triple therapy for patients with hepatitis C
    Sasaki, Masato
    Tanaka, Hideki
    Takeguchi, Masataka
    Mochinaga, Takaho
    Matsushita, Hiroshi
    Kurano, Soutaro
    Nakamura, Aiko
    Yoshida, Kenichi
    [J]. JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2015, 30 : 382 - 382
  • [7] Simeprevir and sofosbuvir for treatment of hepatitis C infection
    Chopp, Shelby
    Vanderwall, Rebecca
    Hult, Amanda
    Klepser, Michael
    [J]. AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2015, 72 (17) : 1445 - 1455
  • [8] Effectiveness and safety of simeprevir-based regimens for hepatitis C in Italy The STlly observational study
    Gaeta, Giovanni Battista
    Aghemo, Alessio
    Menzaghi, Barbara
    D'Offizi, Gianpiero
    Giorgini, Alessia
    Hasson, Hamid
    Brancaccio, Giuseppina
    Palma, Maria
    Termini, Roberta
    [J]. MEDICINE, 2018, 97 (27)
  • [9] Hepatitis C - Simeprevir plus sofosbuvir with genotype 1
    Pommer, Peter
    [J]. ZEITSCHRIFT FUR GASTROENTEROLOGIE, 2016, 54 (06): : 530 - 530
  • [10] Simeprevir and Sofosbuvir for Treatment of Chronic Hepatitis C Infection
    Childs-Kean, Lindsey M.
    Hand, Elizabeth O.
    [J]. CLINICAL THERAPEUTICS, 2015, 37 (02) : 243 - 267
12345